138 Background: LuPSMA is a PSMA-targeted radiopharmaceutical used to treat mCRPC that may impair kidney function, due to PSMA expression on proximal tubular cells and urinary excretion of the radiopharmaceutical. While a short-term decline in estimated glomerular filtration rate (eGFR) has been reported, the incidence of long-term decline, along with clinical and biochemical predictors for decline, has not been well-characterized. Methods: We evaluated consecutive patients with mCRPC treated with ≥3 cycles of LuPSMA at our institution between 6/2022 and 6/2025. Kaplan-Meier and Cox regression models were used to analyze time to eGFR decline, defined as ≥15% decline from baseline eGFR; severity of eGFR decline was further categorized as mild (15-30%), moderate (30-40%), and severe (≥40%). Baseline plasma levels of TNFaR-1, TNFaR-2, YKL-40, MCP-1, and KIM-1 were evaluated in a subset of patients who did (n=23, cases) and did not (n=23, controls) experience ≥15% eGFR decline. Results: 213 patients (median age 72) were included, who received a median of 6 cycles of LuPSMA; median baseline eGFR was 88 mL/min (IQR 73-97). At a median follow-up of 7.1 months (range 0.1). Conclusions: eGFR decline after LuPSMA was common but generally transient, with 90) 104 (49) 31 (46) 2 (60–89) 86 (41) 22 (32) 3 (30–59) 22 (10) 12 (18) 4 (15–29) 0 3 (4)
Tchitchkan et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: